New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesilute vs Exenatide

Vesilute vs Exenatide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesilute
GLP-1 / Weight Loss AgonistsCognitive Enhancement
Exenatide
Summary
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
5 mcg, titrate to 10 mcg
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
  • Blood glucose control in type 2 diabetes
  • Weight loss (average 2–3 kg in clinical trials)
  • Once-weekly extended-release formulation available
  • Reduces appetite and food intake
  • Possible neuroprotective in Parkinson's disease (Phase II trials)
  • Reduces systemic inflammation
  • May protect pancreatic beta cells
  • Cardiovascular neutral or potentially protective
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
  • Nausea (most common, especially initially)
  • Vomiting
  • Diarrhea
  • Headache
  • +4 more
Stacks With